Vanessa Yardley
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 48 publications
Liposomal antimicrobials in the fight against bacterial and fungal pathogens: Clinical successes and development challenges.
Journal: International journal of pharmaceutics: X
Published: October 10, 2025
Clinical and patient-reported outcomes of cutaneous leishmaniasis treatment in Ethiopia: a prospective observational cohort study from two referral hospitals.
Journal: The British journal of dermatology
Published: October 09, 2025
Comparative in vitro susceptibility of clinical Leishmania isolates to miltefosine and oleylphosphocholine.
Journal: Frontiers in pharmacology
Published: August 19, 2025
Comparative assessment of macrophage responses and antileishmanial efficacy in dynamic vs. Static culture systems utilizing chitosan-based formulations.
Journal: PloS one
Published: October 04, 2024
DNDI-6174 is a preclinical candidate for visceral leishmaniasis that targets the cytochrome bc1.
Journal: Science translational medicine
Published: December 13, 2023
Protocol for a prospective observational cohort study of cutaneous leishmaniasis in Ethiopia.
Journal: NIHR open research
Published: October 05, 2023
Favorable Preclinical Pharmacological Profile of a Novel Antimalarial Pyrrolizidinylmethyl Derivative of 4-amino-7-chloroquinoline with Potent In Vitro and In Vivo Activities.
Journal: Biomolecules
Published: March 09, 2023
Efficacy of oleylphosphocholine in experimental cutaneous leishmaniasis.
Journal: The Journal of antimicrobial chemotherapy
Published: February 10, 2023
Artemisinin Cocrystals for Bioavailability Enhancement. Part 2: In Vivo Bioavailability and Physiologically Based Pharmacokinetic Modeling.
Journal: Molecular pharmaceutics
Published: November 08, 2021
Artemisinin Cocrystals for Bioavailability Enhancement. Part 1: Formulation Design and Role of the Polymeric Excipient.
Journal: Molecular pharmaceutics
Published: November 01, 2021
DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral Leishmaniasis.
Journal: Journal of medicinal chemistry
Published: October 29, 2021
Novel Linker Variants of Antileishmanial/Antitubercular 7-Substituted 2-Nitroimidazooxazines Offer Enhanced Solubility.
Journal: ACS medicinal chemistry letters
Published: December 12, 2020
Last Updated: 09/26/2026